On September 18, 2020 Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") reported that, at today’s special meeting, its stockholders approved the proposal to amend Titan’s certificate of incorporation to increase the number of authorized shares of common stock from 125 million to 225 million (the "Amendment") (Press release, Titan Pharmaceuticals, SEP 18, 2020, View Source [SID1234565364]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The voting results are available in our Current Report on Form 8-K filed with the SEC today.

"On behalf of the Board and management team, I would like to thank our stockholders for their continued support and we look forward to updating you on our progress," said Titan’s Executive Chairman, Dr. Marc Rubin.